<DOC>
	<DOCNO>NCT00004860</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness fluorouracil-uracil leucovorin treat elderly patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Fluorouracil-Uracil Leucovorin Treating Elderly Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate elderly patient metastatic colorectal cancer treat fluorouracil-uracil leucovorin calcium ( Orzel ) . II . Evaluate toxicity profile regimen patient population . III . Compare response rate obtain study observe recent phase III study young patient . OUTLINE : Patients receive oral fluorouracil-uracil oral leucovorin calcium ( Orzel ) every 8 hour 28 day . Courses repeat every 35 day absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 20-55 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal adenocarcinoma Measurable disease PATIENT CHARACTERISTICS : Age : 75 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : No serious infection No serious underlie medical condition would preclude protocol therapy No known hypersensitivity fluorouraciluracil leucovorin calcium PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior adjuvant immunotherapy colorectal cancer No concurrent immunotherapy Chemotherapy : At least 6 month since prior adjuvant chemotherapy colorectal cancer No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : See Disease Characteristics At least 6 month since prior adjuvant radiotherapy colorectal cancer Prior radiotherapy locally symptomatic disease allow Surgery : Prior surgery allow Other : No prior therapy metastatic disease No concurrent investigational drug No concurrent halogenated antiviral agent ( e.g. , lodenosine , fialuridine , FMAU , emtricitabine , sorivudine )</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>